But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

PTC Therapeutics (PTCT) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150M upon the closing of the transaction. PTC was granted the ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

November 25, 2024, 06:14 am ET, BY John- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Check the time stamp on ...

Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...